🎬 The Odyssey hits big in Indian box office

Christopher Nolan's film, The Odyssey, has proven to be a huge success at the Indian box office. The movie, starring Matt Damon and Tom Holland, was released in India with significant buzz. Over 32 days, it has earned a net total of 175.95 crore, achieving a nearly 11x opening day multiplier. The film maintained strong audience interest even past its initial two weeks, showing consistent performance. It is projected to finish its lifetime collection between 180-185 crore net. 🤩

🎬 The Odyssey hits Universal's top 5 worldwide

The Odyssey has achieved major box office milestones, entering Universal’s all-time top 5 highest-grossing films. Directed by Christopher Nolan, the movie surpassed The Fate of the Furious worldwide to reach this spot. In its 5th weekend, it earned $23.6 million domestically and $104 million internationally. The mythological epic is currently aiming to beat Jurassic World: Fallen Kingdom for a higher ranking. The film, released on July 17, is projected to earn between $1.6 billion and $1.7 billion globally. 🚀

💰 Aamir Khan's production hits 1000 Cr mark

Batwara 1947 is pushing Aamir Khan's production total past the 1000 crore net mark. This is part of his 14 films produced by Aamir Khan Productions in Indian cinema. Across 13 films, the production house has a total budget of 544 crore and a cumulative collection of 970.43 crore. While his overall ROI is 78.39%, the post-COVID period has seen a slump with several flops. The fate of Batwara 1947 will determine the final box office picture. 🎬

💊 SGLT2 drugs: not all are the same

Six SGLT2 inhibitor drugs share a mechanism but have different approved uses. Dapagliflozin and empagliflozin have indications for heart failure and CKD even without diabetes. Ertugliflozin and bexagliflozin are only approved for glycemic control in T2DM. Sotagliflozin targets heart failure and CKD but lacks a glycemic indication. Clinicians must match the specific labeled indication to the patient, as the amputation warning status also changed.

💰 Sunny Deol's last 5 films: profit or loss?

Sunny Deol's last five films saw producers invest over 500 crore across the projects. Out of these five, only two achieved a clean hit, leading to a 40% success ratio for the actor. Gadar 2 stood out as the top earner, netting 525.50 crore against a 75 crore budget. Despite the low success rate, total net profits reached 496.66 crore from 996.66 crore in collections. The overall financial recovery remains healthy, though Batwara 1947 adds uncertainty. 🎬

💰 Ajay Devgn hits 1375 crore mark with Dhamaal 4

Ajay Devgn surpassed 1375 crore in net collections post-COVID thanks to the performance of Dhamaal 4. This milestone was achieved in the Indian box office while Dhamaal 4 earned 177.75 crore in 39 days. His previous post-COVID total was 1197.87 crore before this latest release. Despite mixed reviews for the film, its performance contributed significantly to his overall tally. With Drishyam 3 coming in October, he is set to cross the 1500 crore mark.

🕷️ Spider-Man: Brand New Day crushes box office targets

Spider-Man: Brand New Day is a massive hit, becoming the first film of 2026 to surpass the $2 billion worldwide mark. The Tom Holland starrer is performing incredibly well in North America, hitting $786.8 million in just 17 days. Internationally, the film has earned $1.2 billion, bringing its global total to $2.02 billion. It has earned a 259.5% gain on its $562.5 million break-even target in only seven days. The movie, released on July 31, is projected to earn between $2.5 billion and $2.7 billion globally. 🕷️

💉 Qdenga paving the way for dengue vaccine access

Three dengue vaccines have received global regulatory approval, including Qdenga, Dengvaxia, and Butantan-DV. Takeda's Qdenga got approval in India on July 2026 from CDSCO, targeting ages 4–60. Clinical data shows Qdenga has 80.2% efficacy against dengue and 90.4% against hospitalization. Vaccination can potentially affect diagnostic tests like RT-PCR shortly after administration. The future market will integrate vaccination, diagnostics, and surveillance efforts. 💉

🔬 TZP resistance not linked to higher death risk in blood infections

A Danish cohort study investigated whether piperacillin-tazobactam resistant blood infections increase mortality risk. Researchers analyzed 34,379 patients with E coli or K pneumoniae BSIs from November 2018 to November 2024. Crude mortality was higher for resistant infections initially, but this difference vanished after adjusting for risk factors. The study concludes that TZP resistance does not equate to a higher mortality risk in this Danish cohort. This finding is relevant given rising resistance concerns in Denmark. 🧐

🎬 DC hits milestone, becomes Wamiqa Gabbi's 3rd biggest film

The Tamil action thriller DC is doing well at the box office despite strong competition from Suriya’s Viswanath & Sons. The film has reached a net total of 56.76 crore in India after 11 days domestically. This achievement makes DC Wamiqa Gabbi’s third highest-grossing film in India. Currently, the movie is on track to potentially surpass her 2025 Hindi film, Bhool Chuk Maaf. However, upcoming releases in Kerala might impact DC's future collections. 🎬

🤔 Tata Sons board divided over Chandrasekaran's exit

A debate is happening among some Tata Sons directors regarding the official response to chairman N Chandrasekaran's decision not to seek reappointment. Sir Dorabji Tata Trust (SDTT) wrote to the board suggesting a selection committee to find a successor. This discussion follows Chandrasekaran's sudden decision, leading to uncertainty about the August 18 AGM. Directors are split on whether to vote on the issue or ask him to reconsider his choice. This situation reflects unease around an unexpected leadership transition at Tata Sons.